We can’t show the full text here under this license.
How GLP-1RA drugs may affect inflammatory skin diseases
Updated
Abstract
Glucagon-like peptide 1 receptor agonists () may improve psoriasis and hidradenitis suppurativa through their effects on inflammation.
- GLP-1RA are used in the treatment of type 2 diabetes and obesity, contributing to glucose control and weight loss.
- These agents are associated with reductions in cardiovascular risk and have immunological and anti-inflammatory effects.
- GLP-1RA could reduce systemic inflammation, which may help improve inflammatory skin diseases.
- The review includes clinical data showing positive effects of GLP-1RA in patients with psoriasis and hidradenitis suppurativa.
- Direct interactions with inflammation and immune cell signaling pathways are discussed as mechanisms of action for GLP-1RA.
Simplified
Key numbers
>15
Improvement in
Observed in patients treated with for T2DM.
5.9 ± 4.6% to 2.9 ± 3.5%
Reduction in γδ T cells
Measured before and after treatment with .
14 patients
Significant improvement in severity
Reported in a study of obese patients receiving liraglutide.